Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs.
eslicarbazepine acetate
focal seizures
healthcare resource utilization
medical charges
Journal
ClinicoEconomics and outcomes research : CEOR
ISSN: 1178-6981
Titre abrégé: Clinicoecon Outcomes Res
Pays: New Zealand
ID NLM: 101560564
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
01
2021
accepted:
12
03
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
29
4
2021
Statut:
epublish
Résumé
To examine the association between initiating first-line (1L) monotherapy with eslicarbazepine acetate (ESL) vs a generic antiseizure drug (ASD) and healthcare resource utilization (HCRU) and charges in adults with treated focal seizures (FS). This was a retrospective analysis of Symphony Health's Integrated Dataverse A total of 250 and 43,220 patients initiated ESL (48.3 years; 57.2% female) or a generic ASD (54.5 years; 58.1% female), respectively. Compared to patients initiating a generic ASD, patients treated with ESL had additional reductions of 11.8 percentage points in the likelihood of any all-cause outpatient visits ( Initiation of ESL as 1L monotherapy was associated with statistically significantly greater reductions in any use of several all-cause and FS-related services, number of visits, and charges compared to initiation of a generic ASD as 1L monotherapy in patients with FS. Initiation of a generic ASD as 1L monotherapy was associated with significantly smaller increases in total prescription charges and ASD-related prescription charges.
Identifiants
pubmed: 33907433
doi: 10.2147/CEOR.S303079
pii: 303079
pmc: PMC8064618
doi:
Types de publication
Journal Article
Langues
eng
Pagination
251-261Informations de copyright
© 2021 Mehta et al.
Déclaration de conflit d'intérêts
DM, BW, TG, and GRW are employees of Sunovion Pharmaceuticals Inc. MD and AJE are employees of Medicus Economics, LLC, which received funding from Sunovion Pharmaceuticals Inc. to participate in this research. The authors report no other conflicts of interest in this work.
Références
Am J Manag Care. 2010 Dec;16(12 Suppl):S331-6
pubmed: 21517648
Acta Neurol Scand. 2021 Jan;143(1):51-55
pubmed: 32762074
Epilepsia. 2015 Sep;56(9):1376-87
pubmed: 26216617
Epilepsy Res. 2009 Jul;85(1):31-45
pubmed: 19369037
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
J Clin Epidemiol. 2013 Aug;66(8 Suppl):S84-S90.e1
pubmed: 23849158
Epilepsy Behav. 2015 Apr;45:169-75
pubmed: 25819943
MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):821-825
pubmed: 28796763
Neurol Ther. 2020 Dec;9(2):585-598
pubmed: 32949379
Epilepsy Behav. 2018 Mar;80:365-369
pubmed: 29415871
Epilepsy Behav. 2018 Aug;85:37-44
pubmed: 29906700
Acta Neurol Scand. 2009 Nov;120(5):281-7
pubmed: 19832771
Seizure. 2013 Jun;22(5):384-9
pubmed: 23478508
BMC Neurol. 2015 Nov 25;15:245
pubmed: 26607561
Neuropsychiatr Dis Treat. 2012;8:455-64
pubmed: 23093905
Expert Rev Neurother. 2019 Oct;19(10):945-954
pubmed: 31257949
Neurology. 2018 Jul 10;91(2):74-81
pubmed: 29898971
J Eval Clin Pract. 2011 Dec;17(6):1231-8
pubmed: 20973870
Brain Behav. 2017 Jan 27;7(3):e00634
pubmed: 28293474
Health Serv Res. 2018 Feb;53(1):175-196
pubmed: 27873305
Ther Adv Drug Saf. 2011 Aug;2(4):141-58
pubmed: 25083209
Epilepsy Behav. 2017 Aug;73:173-179
pubmed: 28641170
Epilepsia. 2002;43 Suppl 4:32-8
pubmed: 12059999
Epilepsia. 2010 May;51(5):838-44
pubmed: 20002150
Epilepsia. 2015 Apr;56(4):546-55
pubmed: 25689448
Epilepsia. 2015 Feb;56(2):244-53
pubmed: 25528898
Pharmacoeconomics. 2010;28(8):675-85
pubmed: 20623993
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):349-55
pubmed: 25474187
Epilepsia. 2018 Feb;59(2):479-491
pubmed: 29369348
Epilepsy Res. 2013 Feb;103(2-3):262-9
pubmed: 22871333